Literature DB >> 2971239

Percutaneous transluminal angioplasty of infrapopliteal vessels: preliminary results and technical considerations.

K T Brown1, N Y Schoenberg, E D Moore, S Saddekni.   

Abstract

Infrapopliteal balloon angioplasty was performed in 11 patients facing reconstructive surgery for limb salvage. Twelve separate sessions of angioplasty were performed, during which 15 of 16 diseased tibial runoff vessels were successfully dilated. Three complications occurred during percutaneous transluminal angioplasty (PTA). One was related to the concomitant use of a thrombolytic agent to open a femoropopliteal bypass graft and not related to the angioplasty itself. No limbs were lost as a result of complications. The procedure was a technical success in nine of 12 cases (75%) and an initial clinical success in eight of the nine that were technically successful (89%). Follow-up ranged from 1 to 22 months. Six of the nine cases (67%) remained clinically successful during this period. Preliminary results suggest that infrapopliteal PTA is a safe and effective alternative to surgical reconstruction in selected patients.

Entities:  

Mesh:

Year:  1988        PMID: 2971239     DOI: 10.1148/radiology.169.1.2971239

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

Review 1.  Peripheral angioplasty balloon technology.

Authors:  A H Matsumoto; K H Barth; J B Selby; C J Tegtmeyer
Journal:  Cardiovasc Intervent Radiol       Date:  1993 May-Jun       Impact factor: 2.740

2.  The use of below-knee percutaneous transluminal angioplasty in arterial occlusive disease causing chronic critical limb ischemia.

Authors:  A M Löfberg; L E Lörelius; S Karacagil; B Westman; B Almgren; D Berqgvist
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Sep-Oct       Impact factor: 2.740

3.  Percutaneous transluminal angioplasty of tibial arteries for limb salvage.

Authors:  M H Saab; D C Smith; P K Aka; R W Brownlee; J D Killeen
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Jul-Aug       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.